TrialCancer science2017
Multicenter phase II study of nivolumab in Japanese patients with relapsed or refractory classical Hodgkin lymphoma.
Dai Maruyama et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this paperpooled ittrialcites it